2023
Entrant Company
Category
Client's Name
Country / Region
Unlocking the Proteome -The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.
By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
Credits
Entrant Company
Min Jin Kook
Category
Interior Design - Leisure & Wellness
Country / Region
United States
Entrant Company
Get Well
Category
Provider & Services - Patient Engagement
Country / Region
United States
Entrant Company
Halteres Associates
Category
Social Media - Public Health
Country / Region
United States
Entrant Company
MI Health Agency
Category
Video, Commercial & Film - Public Service & Activism
Country / Region
Ukraine